School of Pharmacy, Qingdao University, Qingdao 266071, China.
School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao 266113, China.
J Mater Chem B. 2024 Jul 31;12(30):7225-7245. doi: 10.1039/d4tb00756e.
Atherosclerosis (AS) is a significant global health concern due to its high morbidity and mortality rates. Extensive efforts have been made to replicate the cardiovascular system and explore the pathogenesis, diagnosis, and treatment of AS. Microfluidics has emerged as a valuable technology for modeling the cardiovascular system and studying AS. Here a brief review of the advances of microfluidic-based cardiovascular systems for AS research is presented. The critical pathogenetic mechanisms of AS investigated by microfluidic-based cardiovascular systems are categorized and reviewed, with a detailed summary of accurate diagnostic methods for detecting biomarkers using microfluidics represented. Furthermore, the review covers the evaluation and screening of AS drugs assisted by microfluidic systems, along with the fabrication of novel drug delivery carriers. Finally, the challenges and future prospects for advancing microfluidic-based cardiovascular systems in AS research are discussed and proposed, particularly regarding new opportunities in multi-disciplinary fundamental research and therapeutic applications for a broader range of disease treatments.
动脉粥样硬化（AS）是一个严重的全球健康问题，因为其发病率和死亡率都很高。为了复制心血管系统并探索动脉粥样硬化的发病机制、诊断和治疗，已经做出了广泛的努力。微流控技术已成为模拟心血管系统和研究动脉粥样硬化的一种有价值的技术。本文简要综述了基于微流控的心血管系统在动脉粥样硬化研究中的进展。对基于微流控的心血管系统研究的动脉粥样硬化关键发病机制进行了分类和综述，并详细总结了使用微流控技术检测生物标志物的准确诊断方法。此外，还介绍了微流控系统辅助评估和筛选动脉粥样硬化药物的情况，以及新型药物输送载体的构建。最后，讨论并提出了推进基于微流控的心血管系统在动脉粥样硬化研究中的挑战和未来展望，特别是在多学科基础研究和更广泛疾病治疗的治疗应用方面的新机遇。
